Skip to main content

Table 3 Non-hematologic adverse events (AEs) and hematologic laboratory abnormalities (N = 60)

From: Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

AE or laboratory abnormality

n (%)

Grade 1/2

Grade 3

Grade 4

Any grade

Non-hematologic AEs of any cause occurring in ≥ 15% of patients

 Fatigue/asthenia

33 (55)

12 (20)

0

45 (75)

 Diarrhea

33 (55)

3 (5)

0

36 (60)

 Stomatitis, oral discomfort, and related oral syndromes

29 (48)

3 (5)

0

32 (53)

 Dysgeusia

27 (45)

0

0

27 (45)

 Hypertension

18 (30)

8 (13)

0

26 (43)

 Skin and subcutaneous tissue disorders

25 (42)

0

0

25 (42)

 Vomiting

19 (32)

2 (3)

0

21 (35)

 Dyspepsia

20 (33)

0

0

20 (33)

 Epistaxis

18 (30)

2 (3)

0

20 (33)

 Nausea

20 (33)

0

0

20 (33)

 Headache

17 (28)

2 (3)

0

19 (32)

 Decreased appetite

14 (23)

4 (7)

0

18 (30)

 Dry skin

14 (23)

1 (2)

0

15 (25)

 Ejection fraction decreased

10 (17)

3 (5)

1 (2)

14 (23)

 Abdominal pain

11 (18)

0

0

11 (18)

 Hand–foot syndrome and related disorders

8 (13)

3 (5)

0

11 (18)

 Pyrexia

11 (18)

0

0

11 (18)

 Weight decreased

11 (18)

0

0

11 (18)

 Constipation

10 (17)

0

0

10 (17)

 Left ventricular dysfunction

8 (13)

2 (3)

0

10 (17)

 Insomnia

8 (13)

1 (2)

0

9 (15)

 Dyspnea

8 (13)

1 (2)

0

9 (15)

Hematologic laboratory abnormalities

 Leukopenia

46 (77)

4 (7)

1 (2)

51 (85)

 Anemia

46 (77)

2 (3)

0

48 (80)

 Neutropenia

36 (60)

9 (15)

1 (2)

46 (77)

 Lymphopenia

36 (60)

6 (10)

1 (2)

43 (72)

 Thrombocytopenia

34 (57)

6 (10)

3 (5)

43 (72)